QL1706 and Anlotinib Show Promise in Advanced Lung Cancer Phase II/III Trial
A phase II/III study is underway to evaluate QL1706 combined with anlotinib for advanced lung cancer.
Published: August 7, 2026
Updated: August 7, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Lung Cancer
Asset: QL1706
Trial SummaryCLN
Phase II
Oncology / Lung Cancer
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The ongoing phase II/III trial of QL1706 combined with anlotinib could significantly impact treatment options in the advanced lung cancer space. Positive trial results may enhance competitive positioning and market share for the involved therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results and final efficacy data from the trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.